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Chronic pain patients present with cortical gray matter alterations, observed with anatomical magnetic resonance (MR) imaging. Reduced
regional gray matter volumes are often interpreted to reflect neurodegeneration, but studies investigating the cellular origin of gray matter
changesare lacking.Weusedmultimodal imagingtocompare26postmenopausalwomenwithfibromyalgiawith25healthycontrols(agerange:
50–75 years) to test whether regional gray matter volume decreases in chronic pain are associated with compromised neuronal integrity.
RegionalgraymatterdecreaseswerelargelyexplainedbyT1relaxationtimesingraymatter,asurrogatemeasureofwatercontent,andnottoany
substantialdegreebyGABAAreceptorconcentration, an indirectmarkerofneuronal integritymeasuredwith [
18F] flumazenilPET. Inaddition,
theMR spectroscopymarker of neuronal viability,N-acetylaspartate, did not differ between patients and controls. These findings suggest that
decreased gray matter volumes are not explained by compromised neuronal integrity. Alternatively, a decrease in neuronal matter could be
compensated forbyanupregulationofGABAAreceptors.Therelationbetweenregional graymatterandT1relaxation timessuggestsdecreased
tissuewater content underlying regional graymatter decreases. In contrast, regional graymatter increases were explained by GABAA receptor
concentration in addition to T1 relaxation times, indicating perhaps increased neuronal matter or GABAA receptor upregulation and inflam-
matory edema.Byproviding informationon thehistological origins of cerebral graymatter alterations in fibromyalgia, this study advances the
understanding of the neurobiology of chronicwidespread pain.
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Introduction
Brain atrophy occurs in a variety of different neurological and
psychiatric conditions and was traditionally identified postmor-
tem. With the advent of high-resolution anatomical MRI, it has
become possible to analyze gray matter volumes (GMVs) in vivo
and to detect subtle, regionally confined decreases in cerebral
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Significance Statement
Regional gray matter alterations in chronic pain, as detected with voxel-based morphometry of anatomical magnetic resonance
images, are commonly interpreted to reflect neurodegeneration, but this assumption has not been tested. We found decreased
gray matter in fibromyalgia to be associated with T1 relaxation times, a surrogate marker of water content, but not with GABAA
receptor concentration, a surrogate of neuronal integrity. In contrast, regional gray matter increases were partly explained by
GABAA receptor concentration, indicating some form of neuronal plasticity. The study emphasizes that voxel-basedmorphome-
try is an exploratory measure, demonstrating the need to investigate the histological origin of gray matter alterations for every
distinct clinical entity, and advances the understanding of the neurobiology of chronic (widespread) pain.
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gray matter. Regional gray matter decreases have been described
in patients with Alzheimer’s disease, Parkinson’s disease, and
schizophrenia (Mueller et al., 2012a, b), among others. Chronic
pain is no exception and is associated with regional GMV de-
creases in several cortical and subcortical areas, including the
cingulate cortex, insula, prefrontal cortex, and the thalamus, as
confirmed in meta-analyses (Davis and Moayedi, 2013; Small-
wood et al., 2013).
Neurodegeneration, the progressive damage of neurons, is
known to occur in many conditions involving brain atrophy. In
Alzheimer’s disease, for example, hippocampal gray matter de-
creases as detected with MRI were related to decreased numbers
of neurons (Bobinski et al., 2000; Duyckaerts et al., 2009). Neu-
rodegeneration provides an attractive explanation for the delete-
rious effects chronic pain has on cognitive and emotional
processing (Bushnell et al., 2013). However, whether GMV de-
creases in chronic pain are associated with compromised neuro-
nal integrity has not been tested.
In addition to regional gray matter decreases, increases are
observed in chronic pain, albeit less extensively and less consis-
tently (Davis and Moayedi, 2013; Smallwood et al., 2013). We
have speculated that regional gray matter increases reflect su-
praspinal inflammation in chronic pain (Schweinhardt et al.,
2008). Alternatively, increased gray matter in chronic painmight
be caused by increased use of certain neuronal populations, akin
to plastic changes in synapses and neural processes described for
learning (e.g., Anderson, 2011; Draganski et al., 2011; for review,
see Zatorre et al., 2012). Similar to gray matter decreases, tissue
properties underlying gray matter increases in chronic pain have
not been investigated.
Using multimodal imaging, we aimed to better understand
the nature of cerebral gray matter alterations in fibromyalgia, in
which the cardinal symptom is chronic widespread pain (Mease
et al., 2009). The assessment of regional GMVs with high-
resolution T1-weightedMRI, as done in previous studies, enables
the investigation of subtle changes in regional GMVs; however, it
cannot determine which tissue or cell types are affected. There-
fore, we complemented GMV measures with [18F]flumazenil
PET, proton magnetic resonance (MR) spectroscopy, and voxel-
based quantitative T1 relaxometry. Flumazenil binds to the ben-
zodiazepine site of the -aminobutyric acid (GABAA) receptor,
which is densely expressed at inhibitory synapses in the cortex
(Holthoff et al., 1991; Sette et al., 1993;Heiss et al., 1998). Because
the benzodiazepine-GABAA receptor complex is located on neu-
rons, [18F]flumazenil PET has been used as a surrogatemarker of
neuronal density in gray matter (la Fouge`re et al., 2011) and of
neuronal integrity (Heiss et al., 2001). The concentration of
N-acetylaspartate, measured with proton MR spectroscopy,
served as additional read-out of neuronal viability (Moffett et al.,
2007). Finally, quantitative T1 relaxometry was used as a surro-
gate measure of tissue water content (Fatouros et al., 1991;
Gelman et al., 2001) because alterations in water content might
influence apparent gray matter (Lorio et al., 2016).
Materials andMethods
Participants
Postmenopausal women were studied because fibromyalgia predomi-
nantly affects women (Staud, 2006) and because premenopausal and
postmenopausal fibromyalgia patients have been reported to show dif-
ferent patterns of regional graymatter alterations (Ceko et al., 2013). The
McGill Institutional Review Board approved the study, and participants
gave written informed consent before inclusion. Exclusion criteria were:
pain conditions other than fibromyalgia, uncontrolled medical condi-
tions, any psychiatric or neurological disorders, and body mass index
30 kg/m2. Participants using benzodiazepine medication more than
once a week were excluded. Participants using benzodiazepines occa-
sionally (4 patients once a week, 2 patients biweekly) were offmedication
for at least 48 h before the PET scan to avoid potential interactions of
benzodiazepines with the radiotracer. Of 59 participants recruited, 8
were excluded from analysis: 4 participants had one or more missing
imaging modalities, 3 had poor quality PET data, and 1 had visible atro-
phy. The final sample comprised 26 patients and 25 controls with com-
plete imaging data. The healthy control group was matched to the
fibromyalgia group for age, body mass index, education level, income,
and physical activity level [short version of the International Physical
Activity Questionnaire (Craig et al., 2003)] because these factors can
influence regional GMVs. An experienced rheumatologist (M.-A.F.)
confirmed the diagnosis of fibromyalgia according to the 2012 Canadian
Guidelines (Fitzcharles et al., 2013), before inclusion.
Participants took part in three 1.5-h-long sessions: a psychophysical/
questionnaire session, one MRI, and one PET session. Thirty-seven par-
ticipants of 51 had the three sessions within a 2 week period, nine within
1month, and four within 3months. For one participant, theMRI session
was separated from the PET and psychophysical session by 1 year because
poor data quality required repeating the MRI session.
Psychophysical/questionnaire session
Participants were asked about their current pain level and tested for pain
sensitivity (pressure pain on the thumb), completed the BeckDepression
Inventory (Beck et al., 1961), the Hospital Anxiety and Depression Scale
(Zigmond and Snaith, 1983), the Pain Catastrophizing scale (Sullivan et
al., 1995) (maximum score 52, clinically relevant score 30), and the
Fibromyalgia Impact Questionnaire (Bennett, 2005). Participants were
also assessed using the Attention Network Test (Fan et al., 2002) and the
Auditory Consonant Trigram test (Stuss et al., 1988). The data from the
pain testing as well as the cognitive testing are not included in this report.
Image acquisition
MRI and spectroscopy. MRI was performed using a 3 tesla Tim Trio Sie-
mens scanner (Siemens Medical Solutions) with a 12-channel head coil.
Three types of data were acquired: anatomical T1-weighted images to
assess regional GMVs, absolute T1 relaxation times to assess water con-
tent, and proton MR spectroscopy to measure metabolite levels, specifi-
callyN-acetylaspartate (NAA) andN-acetylaspartyl-glutamate (NAAG).
For T1-weighted images, a 3DMP-RAGE sequence with the following
parameters was used: repetition time 2300 ms, echo time 2.98 ms, flip
angle 9°, field of view 256 mm, 192 slices in the sagittal plane, resolution
1 1 1 mm; acquisition time 10 min.
To compute maps of absolute T1 relaxation times, T1 mapping was
performed using Variable Flip Angle mapping (Deoni et al., 2005) with
the following parameters: repetition time 15 ms, echo time 3.21 ms, flip
angle 3° and 20°, field of view 256 mm, 160 slices, resolution 1 1 1
mm.TheActual Flip Angle sequence (Yarnykh, 2007)was used to correct
for inhomogeneities of the radiofrequency magnetic field (B1), with the
following parameters: repetition time 20 ms, N 5, echo time 3.53 ms,
flip angle 60°, field of view 256 mm, 44 slices, slice thickness 4 mm,
in-plane resolution 2 2 mm; acquisition time 19 min.
Single-voxel proton MR spectroscopy was performed using a Point
Resolved Spectroscopy sequence (Bottomley, 1984) with the follow-
ing parameters: repetition time 3000 ms, echo time 30 ms, 196 acqui-
sitions; acquisition time 10 min. A 20  40  15 mm voxel was
positioned in the anterior cingulate cortex (ACC) (Fig. 1) because it
consistently displays GMV decreases in chronic pain including fibro-
myalgia (Smallwood et al., 2013), plays an important role in pain
processing, and is more suitable for MR spectroscopy compared with
some other brain regions because of the relative lack of susceptibility
artifacts and signal inhomogeneities.
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PET. Data were acquired using an ECAT
High-Resolution Research Tomograph (Sie-
mens Medical Solutions), which has a spatial
resolution of 2.3–3.4 mm at FWHM. The ra-
diopharmaceutical [ 18F]flumazenil was syn-
thesized as published previously (Massaweh et
al., 2009). After a transmission scan for atten-
uation correction (137Cs-source), 370 MBq
of [ 18F]flumazenil was injected intravenously
as a slow bolus over 60 s. List-mode data were
acquired for 60 min after injection and were
subsequently binned into fully 3D sinograms
for a total of 17 time frames (40, 20, 2 30, 3
60, 4 150, 3 300, and 3 600 s).
Image analysis
Data were analyzed in a blinded fashion with
any group identifying information (patient or
control) removed. The quality of the raw data
from each imaging modality as well as at each
processing step in each modality’s processing
pipeline was carefully checked.
Voxel-based morphometry (VBM)
Regional GMVs were obtained by VBM analy-
sis (Ashburner and Friston, 2000) using the
VBM8 toolbox (RRID:SCR_014196) in the
Statistical ParametricMapping software (SPM8 revision 4667,Wellcome
Trust Centre for Neuroimaging, RRID:SCR_007037) on the anatomical
T1-weighted images. The following analysis steps were performed: (1)
Image normalization to the MNI standard space using linear and non-
linear transformations (sixth generation nonlinear International Con-
sortium for Brain Mapping template) and tissue probability maps. (2)
Segmentation of the normalized images into gray matter, white matter,
andCSF using the intensity distribution of the images. (3)Modulation of
the gray matter segments (i.e., the intensity of each voxel was multiplied
by the amount of contraction or expansion estimated by the nonlinear
transformation to obtain relative volumes corrected for brain size and
gross anatomical differences). (4) The modulated normalized gray mat-
ter segments were spatially blurred with a 7  7  7 mm (FWHM)
Gaussian smoothing kernel (Fig. 2).
Voxel-based relaxometry (VBR)
To compute T1 maps, the B1 maps were used to correct transmit field
inhomogeneities, ensuring that the flip angles in the Variable Flip Angle
acquisitions are accurate across the field of view. The two corrected Vari-
able Flip Angle images were used to infer absolute T1 relaxation times
(Deoni et al., 2005), which are independent of the acquisition parameters
and comparable between different scanners and sites (Cheng et al., 2012).
The resulting maps, which reflect extracellular and intracellular water
(Cheng et al., 2012), were masked for the head. To analyze T1 relaxation
times on a voxelwise basis, we developed an analysis pipeline specific for
this purpose: (1) Each participant’s voxelwise map of T1 relaxation time
was registered to the corresponding T1-weighted image. (2) The nons-
moothed gray matter segment output from VBM8 was thresholded to
keep only voxels containing at least 90% of gray matter, then binarized.
(3) The binarized graymatter segment was used tomask the T1maps. (4)
To spatially normalize the T1 maps, the transformation matrix (from
native T1-weighted image space to standard MNI space) was applied to
the masked map of T1 relaxation times. The T1 maps were not modu-
lated (not multiplied by the amount of contraction or expansion esti-
mated by the nonlinear transformation) to preserve the quantitative
information. (5) The resulting T1 maps in gray matter were spatially
blurred with a 7  7  7 mm (FWHM) Gaussian smoothing kernel
(Fig. 2).
To test the validity of the measurements, we added an alternative
analysis to infer water content based on proton density (PD) measure-
ments, obtained from the same T1 mapping protocol. To circumvent
problems associated with high correlations between T1 and PD (Fatou-
ros et al., 1991), the PDmaps were normalized by the average PD in CSF,
as per Mezer et al. (2013). Thereby, the resulting water volume fraction
(WVF) maps (WVFvoxel  PDvoxel/PDCSF) are highly reproducible
across subjects and field strengths (Mezer et al., 2013). The remaining
processing steps (coregistration with the T1-weighted scan, masking of
the gray matter, application of transformations to standard space, and
smoothing) were identical to the analysis of T1 relaxation times.
Proton MR spectroscopy
Postprocessing of the spectroscopy data was performed using LCModel
(Provencher, 1993) (RRID:SCR_014455), which explicitly fits the base-
line, thereby achieving high sensitivity. LC Model is an operator-
independent software that fits in vivometabolite spectra by using model
spectra previously acquired from similar scanning conditions from var-
ious compounds in phantom solutions. Concentration ratios relative to
Creatine (Cr) were computed for NAA  NAAG (denoted tNA). In
mature brain, NAA and NAAG are present exclusively in neurons and
their processes, and thus serve as markers of neuronal viability (Moffett
et al., 1991). Given that theNAAG resonance ismuch smaller than that of
NAA, and there is considerable overlap, the total signal is more robustly
quantified. Quality control criteria for retaining spectra included
Cramer-Rao SD of the total N-acetyl group fit10% (mean SD: 3
0.8%), peak FWHM 0.08 ppM, spectrum signal-to-noise ratio 10
(mean SD: 37 7), and low residual spectrum.GMV, nondisplaceable
binding potential (BPND), and water content were extracted from the
spectroscopy voxel volume in native space. The MR spectroscopy voxel
masks were created from information in the raw spectroscopy data.
PET
We computed the BPNDmaps from the PET images. BPND of a reversibly
binding radioligand is related to the maximum available concentration
of its receptor (Bmax) accounting for the binding affinity of the tracer (A)
and the fraction (fND) of nondisplaceable tracer bound (i.e., tracer irre-
versibly bound to other molecules than the receptor) in the tissue
(BPND  fND  Bmax  A). Thus, BPND of flumazenil represents the
signal in the brain arising from the fraction of radiotracer that is specif-
ically bound to the benzodiazepine site of GABAA receptors. Lower
flumazenil BPND indicates a lower concentration of GABAA receptors,
which could be caused by receptor downregulation, decreased neuronal
matter, or compromised neuronal integrity (Heiss et al., 2001).
Raw PET images were reconstructed by fully 3D filtered back-
projection by a 3D reprojection method and corrected for participants’
head motion. The BPND maps were computed with the “iterative
deconvolution with surface-based anatomically constrained filtering”
Figure 1. ProtonMR spectroscopy voxel. Localization of the 20 40 15mmvoxel in the ACC forMR spectroscopy in a single
subject.
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(idSURF)method as published by Funck et al. (2014). The idSURF algo-
rithm corrects for partial volume effects and reconstructs a high-
resolution signal in the cortical gray matter in MNI standard space. (1)
The idSURF algorithm uses the representation of the volume above the
white matter-gray matter surface and below the gray matter-CSF surface
as a spatial constraint to the PET signal. (2) To estimate BPND, the Logan
plot is applied to the high-resolution data using the white matter seg-
ments as low receptor density reference region because there are no
benzodiazepine-GABAA receptor complexes on myelinated axons
(Hammers et al., 2003). The white matter segments were eroded to limit
radioactivity spill over from adjacent gray matter. (3) BPND maps were
back-transformed to native MRI space, and the VBM8 transformation
was applied to the data. (4) Resulting BPND maps in gray matter were
spatially blurred with a 7  7  7 mm FWHM Gaussian smoothing
kernel (Fig. 2).
Statistical analysis
Group differences between fibromyalgia patients and healthy controls. Clin-
ical variables and questionnaire data were compared between groups
using two-sample two-sided Student’s t tests in SPSS (version 17.0,
RRID:SCR_002865). The tNA/Cr ratio in the ACC was compared be-
tween groups using a univariate GLMwith the percentage of gray matter
in the spectroscopy voxel and/or age as covariates of no interest.
Statistical analysis of VBM was performed in SPM8 with nonunifor-
mity smoothness correction (Worsley et al., 1999). A GLM was used for
GMV analysis to compare patients and controls with age as a covariate of
no interest. Two approaches were used for statistical inference: (1) a
voxel-based threshold ofZ 2.3 (corresponding to a p 0.01) corrected
for spatial extent across the whole brain using cluster-level correction
based on random field theory at p 0.05 (Worsley et al., 2004); and (2)
a voxel-based threshold of Z 2.3 combined with a more lenient extent
threshold of k  200 contiguous voxels to reduce the probability of a
Type II statistical error.
Contribution of BPND and water content to GMV
Areas showing GMVs differences between patients and controls were
used as regions of interest (ROIs) in which flumazenil BPND and water
contentwere investigated.Hierarchicalmultiple regression analyseswere
used to test whether BPND, water content, and group (patients or con-
trols), in this order, significantly contributed to GMV. Visual inspection
of scatter plots indicated that the assumptions of linearity were met. The
studentized residuals were normally distributed and homoscedastic. We
Figure 2. Processing pipelines. Middle, VBM analysis of GMVs. Other panels, Voxel-based analysis pipelines that we developed specifically for analysis of BPNDmaps for flumazenil PET (left), and
voxel-based relaxometry (VBR) analysis of T1 maps, a surrogate marker of water content (right). Blue box represents data in standard space (MNI space).
Table 1. Participants’ demographic and clinical dataa
Patients Controls
Group
difference ( p)Mean SD Mean SD
Age (yr) 61 5.4 61 7.6 0.86
BMI (kg/m 2) 26 3.7 25 3.9 0.27
Education (yr) 15 4.1 16 4.0 0.18
Income (in 1000$/year) 44 24 40 28 0.62
IPAQ score (MET, minutes/week)b 2831 3717 2735 2912 0.92
GMV (ml) 595 42 578 32 0.12
White matter volume (ml) 481 56 467 38 0.29
CSF (ml) 230 37 227 34 0.76
Total volume (ml) 1307 100 1273 82 0.19
Time since diagnosis (yr) 9 8 NA NA
Symptom duration (yr) 16 9 NA NA
Current pain level (1–10) 4.8 2.2 0.7 1 0.001
BDI score (1–63) 16 10 4 4 0.001
HADS score (1–42) 16 6 6 4 0.001
PCS score (1–52) 22 13 7 9 0.001
FIQ score (1–100) 51 18 7 8 0.001
aBMI, Body mass index; IPAQ, International Physical Activity Questionnaire; BDI, Beck Depression Inventory; HADS,
Hospital Anxiety andDepression Scale; FIQ, Fibromyalgia ImpactQuestionnaire; PCS, Pain Catastrophizing Scale; NA,
not applicable. Brain volumeswerederived fromnative space. Total volume refers tograymatterwhitematter
CSF. FIQ is based on questions, such as “Were you able to do laundry with a washer and dryer (in the past week)?”
Therefore, the FIQ can be completed by control participants.
bMET, Metabolic equivalent intensity levels (median); 1 MET is considered a restingmetabolic rate obtained during
quiet sitting. Participants were on average minimally active.
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included interaction terms between BPND and group as well as water
content and group to assess the influence of group on the relationship
between gray matter and BPND or water content. The mean values of
modulated graymatter density, BPND, andwater contentwithin theROIs
in standard space were extracted in MATLAB 8.1 (The MathWorks,
RRID:SCR_001622) using the spm_summarise SPM8 function. The
modulated gray matter density in each ROI was transformed to volume
by taking into account voxel size as inKurth et al. (2015). GMV (inmm3)
served as the dependent variable; BPND (unitless), water content (T1
relaxation times in seconds, the longer T1, the more water in the tissue),
group, and the interaction terms served as the explanatory variables.
Finally, the effect size and power of the BPND difference between groups
were calculated for each ROI.
Correlation with clinical variables
Pearson’s correlation analyses (one-tailed) were performed to assess the
clinical significance of the GMV changes in patients. We tested whether
GMVs in areas of decreased gray matter were negatively correlated with
questionnaire scores (Fibromyalgia Impact Questionnaire, Hospital
Anxiety and Depression Scale, Beck Depression Inventory, Pain Cata-
strophizing Scale), current pain level, time since diagnosis, and symptom
duration. Inversely, we tested whether GMVs in areas of gray matter
Figure 3. GMV decreases in patients with fibromyalgia and their relationship with tissue water content. Whole-brain map of GMV decreases in patients compared with controls. Results are
presentedat a voxelwise thresholdof z2.3 anda cluster-extent thresholdof k200, overlaid on themeananatomical imageof thewhole sample (N51). Scatter plots representGMV (inmm3)
and T1 time in seconds (a surrogate for water content) in each significant cluster. Axial images are displayed in neurological convention. Right, Right hemisphere.
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increases were positively correlated with clinical variables. Correlation
analyses were considered exploratory and therefore nor corrected for
multiple comparisons.
Replication of PET and VBM relationship
To test whether we could replicate a previously reported relationship
between PET and VBMmeasures, we tested our healthy control group
for the significant positive correlations between gray matter density
and flumazenil BPND described by Duncan et al. (2013) for young
healthy adults. We followed their approach and conducted weighted
least square regression analyses between gray matter density and
BPND in regions defined by the Ju¨lich histological atlas (Eickhoff et
al., 2006, 2007). The weighting was computed as the inverse of the
variance of the BPNDmeasure within each anatomical region, for each
subject.
Results
Participant characteristics
Patients had on average moderate pain at the time of the psycho-
physical/questionnaire session (mean  SD: 4.8  2.2 on an
11-point numerical rating scale) and amoderate impact of fibro-
myalgia on functioning as measured by the Fibromyalgia Impact
Questionnaire. Patients and controls did not differ significantly
with respect to age, body mass index, education level, income, or
physical activity levels. Despite having statistically higher scores
on the Beck Depression Inventory, the Hospital Anxiety and De-
pression Scale and the Pain Catastrophizing Scale, none of the
patients had clinically significant levels of depression, anxiety, or
pain catastrophizing as determined by questionnaire cutoffs. To-
tal brain volume and volumes of gray matter, white matter, and
CSF were not significantly different in patients compared with
healthy controls (Table 1).
GMV decreases in patients compared with controls
In line with previous studies, fibromyalgia patients presented
GMV alterations in several cortical regions. Regional GMV was
decreased in patients compared with healthy controls in the pos-
terior cingulate cortex (PCC) and precuneus, significantly when
corrected for cluster extent on a whole-brain level. ACC, bilateral
insula, right medial prefrontal cortex (MPFC), left precentral
gyrus, left middle temporal gyrus (MTG), and right fusiform
gyrus showed decreased GMV at the more lenient statistical
threshold of 200 contiguous voxels (Fig. 3; Table 2).
In most regions of decreased GMV, T1 relaxation times (a
surrogate measure of water content) and group (patient or con-
trol) accounted for a large proportion of the variance, with no
significant contribution of flumazenil BPND, measuring GABAA
receptor concentration (Fig. 3). T1 relaxation time accounted for
between 13% (ACC) and 55% (MPFC) of the variance; only in
the fusiform gyrus did T1 relaxation time not contribute signifi-
cantly to the hierarchical multiple regression model. Only in the
left insula, MPFC, and MTG did GABAA receptor concentration
explain some gray matter variance (11%, 12%, and 12%, respec-
tively). Closer inspection revealed a negative relationship in the
left insula: the less GMV, the higher the concentration of GABAA
receptors. In the precuneus, group influenced the relationship
between GABAA receptor concentration and GMV: patients
showed a significant positive relationship betweenGABAA recep-
tor concentration and GMV, which was absent in the controls.
The results in regions of decreased GMV were largely un-
changed when T1 relaxation time was entered first in the regres-
sion model. The results were very similar when using the proton
density derived metric (Mezer et al., 2013) instead of T1 relax-
ation times as a measure of water content. Detailed results of the
regression analysis are found in Table 3. The finding that GABAA
receptor concentration did not contribute to the graymatter vari-
ance in regions of decreased gray matter in patients is corrobo-
rated by the observation that GABAA receptor concentration was
not lower in patients than in controls in any of the ROIs (highest
effect size 0.12, power 0.07).
GMV in the ACC spectroscopy voxel was not significantly
different in patients compared with controls (patients mean 
SD: 6727 458 mm3, controls: 6842 609 mm3, F 0.54, p
0.465) or when controlling for age. tNA/Cr ratios were in line
with literature values: 1.12 0.11 for patients and 1.11 0.11 for
controls (Nordahl et al., 2002). There was no group difference for
tNA/Cr ratios when controlling for gray matter amount in the
voxel, for age, or for both, indicating that neuronal viability was
not affected in the ACC of the patients. There was no correlation
between tNA/Cr ratios andGABAA receptor concentration in the
spectroscopy voxel across the two groups (r	0.14, p 0.314).
GMV increases in patients compared with controls
In line with the literature, increases of GMVs in fibromyalgia
patients were less pronounced than decreases. Increased GMVs
were found in the angular gyrus, cuneus, and right postcentral
gyrus (Fig. 4; Table 2). In contrast to regions with GMV de-
creases, GABAA receptor concentration explained more variance
than tissue water content. Specifically, GABAA receptor concen-
tration explained 32% of the variance in the angular gyrus, 70%
in the cuneus, and 22% in the postcentral gyrus; tissue water
Table 2. VBM analysis resultsa
Region
Cluster
corrected
p
Cluster
extent
(no. of voxels) Z score
Coordinates (mm)
x y z
Gray matter decreases in patients compared with controls
PCC R 0.011b 830 3.82 15 	34 34
2.98 10 	24 33
2.66 16 	40 55
Fusiform gyrus R 0.087 644 3.66 36 	49 	21
3.29 39 	60 	15
2.49 27 	60 	17
Insula L 0.126 383 3.4 	48 	6 9
2.79 	39 	10 7
Insula R 0.133 349 3.21 42 8 10
MPFC R 0.096 225 3.2 2 56 6
2.73 	2 64 10
2.66 0 60 	5
ACC L 0.067 537 3.19 	3 23 30
2.99 	14 18 25
2.36 	15 3 30
Precuneus R 0.022b 651 3.14 16 	51 24
2.94 33 	48 0
2.72 21 	49 13
Precentral gyrus L 0.207 448 3.04 	58 	3 37
2.6 	56 5 21
MTG L 0.154 282 3.03 	44 	37 3
2.8 	46 	40 	6
2.77 	44 	28 	2
Gray matter increases in patients compared with controls
Angular gyrus L 0.05 594 3.83 	39 	60 40
2.68 	33 	63 55
Cuneus R 0.113 234 3.38 12 	81 46
3.27 6 	76 39
Postcentral gyrus R 0.262 306 3 40 	25 34
2.97 36 	31 46
2.37 39 	27 56
aWhole-brain results are presented at a voxel-wise threshold of Z 2.3 and cluster extent of k 200 contiguous
voxels. L, Left; R, right.
bSignificant with cluster-level correction across the whole brain at p 0.05.
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Table 3. Multiple regression resultsa
Water content Proton density
Adjusted R 2 R 2 change F p Adjusted R 2 R 2 change F p
Gray matter decreases in patients compared with control
PCC R
BPND 0.35 0.06 3.2 0.082 0.53 0.06 3.2 0.082
T1/PD 0.20b 12.7b 0.001b 0.40b 35.5b 0.001b
Group 0.12b 9.2b 0.004b 0.08b 8.3b 0.006b
Group BPND 0.04 2.8 0.102 0.04 3.9 0.055
Group T1/PD 0.00 0.1 0.730 0.00 0.0 0.961
Fusiform R
BPND 0.01 0.4 0.509 0.33 0.01 0.4 0.509
T1/PD 0.01 0.6 0.452 0.04 2.1 0.158
Group 0.31b 21.2b 0.001b 0.30 21.2b 0.001b
Group BPND 0.02 1.4 0.249 0.02 1.3 0.253
Group T1/PD 0.05 3.8 0.058 0.03 2.2 0.141
Insula L
BPND 0.31 0.11
b 5.9b 0.018b 0.38 0.11b 5.9b 0.018b
T1/PD 0.15b 9.8b 0.003b 0.23b 16.6b 0.001b
Group 0.11b 8.1b 0.007b 0.08b 6.1b 0.017b
Group BPND 0.01 0.4 0.515 0.00 0.3 0.585
Group T1/PD 0.00 0.1 0.820 0.02 2.0 0.168
Insula R
BPND 0.34 0.06 3.4 0.072 0.42 0.06 3.4 0.072
T1/PD 0.23b 15.3b 0.001b 0.29b 21.8b 0.001b
Group 0.11b 8.9b 0.005b 0.10b 8.3b 0.006b
Group BPND 0.00 0.1 0.702 0.01 1.1 0.298
Group T1/PD 0.00 0.1 0.786 0.01 0.8 0.377
MPFC R
BPND 0.68 0.12
b 6.6b 0.013b 0.77 0.12b 6.6b 0.013b
T1/PD 0.55b 79.3b 0.001b 0.65b 131.1b 0.001b
Group 0.04b 6.5b 0.014b 0.03b 6.2b 0.016b
Group BPND 0.01 1.0 0.326 0.00 0.3 0.578
Group T1/PD 0.00 0.3 0.594 0.00 0.9 0.347
ACC L
BPND 0.29 0.00 0.0 0.930 0.32 0.00 0.0 0.930
T1/PD 0.13b 6.9b 0.012b 0.20b 11.8b 0.001b
Group 0.21b 14.6b 0.001b 0.16b 11.9b 0.001b
Group BPND 0.02 1.6 0.206 0.03 1.9 0.180
Group T1/PD 0.00 0.0 0.861 0.00 0.2 0.695
Precuneus R
BPND 0.62 0.02 0.8 0.376 0.59 0.02 0.8 0.376
T1/PD 0.42b 35.1b 0.001b 0.41b 34.0b 0.001b
Group 0.15b 17.3b 0.001b 0.15b 16.8b 0.001b
Group BPND 0.06
b 7.3b 0.010b 0.05b 5.8b 0.020b
Group T1/PD 0.02 2.0 0.168 0.01 0.7 0.398
Precentral L
BPND 0.38 0.00 0.0 0.925 0.40 0.00 0.0 0.925
T1/PD 0.36b 27.3b 0.001b 0.40b 31.3b 0.001b
Group 0.06b 4.8b 0.033b 0.04 3.7 0.061
Group BPND 0.02 1.4 0.249 0.02 1.4 0.246
Group T1/PD 0.00 0.2 0.650 0.00 0.0 0.828
MTG L
BPND 0.45 0.12
b 6.5b 0.014b 0.45 0.12b 6.5b 0.014b
T1/PD 0.34b 30.0b 0.001b 0.35b 31.0b 0.001b
Group 0.03 2.6 0.116 0.03 2.8 0.098
Group BPND 0.01 0.5 0.471 0.01 0.5 0.505
Group T1/PD 0.01 0.9 0.354 0.01 0.6 0.431
Gray matter increases in patients compared with controls
Angular gyrus L
BPND 0.56 0.32
b 22.7b 0.001b 0.61 0.32b 22.7b 0.001b
T1/PD 0.22b 22.0b 0.001b 0.28b 34.0b 0.001b
Group 0.06b 6.4b 0.015b 0.04b 4.6b 0.038b
Group BPND 0.00 0.0 0.899 0.01 0.6 0.439
Group T1/PD 0.01 1.5 0.225 0.01 0.6 0.430
Table Continued
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content an additional 22%, 12%, and 18%, respectively. When
water content was included first in the regression model, the
variance explained by water content increased, indicating that
some of the explained variance could not uniquely be ascribed to
GABAA receptor concentration or water content. Because the
variance explained by GABAA receptor concentrationand tissue
water was largely separable for areas of decreased GMV, this sug-
gests that GABAA receptor concentration and water content
change concomitantly in areas of GMV increase. The results of
the regression analysis were very similar when proton density was
used instead of T1 relaxation times. The factor “group” had no
influence on the relationship betweenGMVandGABAA receptor
concentration or water content (Table 3).
Correlation with clinical variables
GMVin thePCCwasnegatively correlatedwith time sincediagnosis
(r  	0.51, p  0.004) and symptom duration (r  	0.33, p 
0.048), and GMV in the ACC was negatively correlated with time
since diagnosis (r	0.52, p 0.007). This means that the longer
the patients have had fibromyalgia, the less graymatter patients had.
Therewasalsoa trend foranegativecorrelationbetweenGMVinthe
PCC and depression scores from the Hospital Anxiety and Depres-
sionScale (r	0.29,p0.073)andtheBeckDepressionInventory
(r	0.27, p 0.091) (i.e., the higher the score on the depression
scales, less GMVwas present).
In the regions of increases, GMV in the angular gyrus was
positively correlated with current pain level (r 0.35, p 0.04),
the anxiety subscale of theHospital Anxiety andDepression Scale
(r  0.36, p  0.034), and the Pain Catastrophizing Scale (r 
0.36, p  0.035). This means that the more severe the pain and
psychological symptoms, the more gray matter patients had in
this region.
Replication of PET and VBM relationship
We largely replicated the findings of positive relationships be-
tween gray matter density and flumazenil BPND by Duncan et al.
(2013) (Table 4). In addition to validating theVBMand the BPND
measurements in the present study, this shows that positive rela-
tionships between GMVs and flumazenil BPNP are preserved in
postmenopausal women.
Discussion
Here, we investigated the histological underpinnings of regional
gray matter alterations in chronic pain using multimodal imag-
ing. Gray matter decreases were largely explained by T1 relax-
ation times, a surrogate measure of water content, and not to
any substantial degree by GABAA receptor concentration. In
contrast, gray matter increases were explained by GABAA re-
ceptor concentration, in addition to T1 relaxation times. To
the best of our knowledge, this is the first time that GABAA
receptor concentration and T1 relaxation times were mea-
sured and combined to understand the basis of gray matter
alterations in chronic pain.
GABAA is themost widespread inhibitory receptor in the CNS
(Nutt andMalizia, 2001),mainly localized on postsynapticmem-
branes (for review, seeWaldvogel and Faull, 2015), and expressed
only weakly in non-neuronal tissue (Fraser et al., 1995; Kullmann
et al., 2005). The difference in GABAA receptor concentration
between neuronal and non-neuronal tissues forms the basis for
using binding of flumazenil, an antagonist at the benzodiazepine
binding site of the GABAA receptor, as a surrogate of neuronal
integrity (Heiss et al., 1998) or density (la Fouge`re et al., 2011).
The finding that regional gray matter decreases were not ex-
plained by GABAA receptor concentration likely indicates that
neurons are unaffected in those areas. Alternatively, neurodegen-
eration is present in patients with fibromyalgia but is masked by
concomitant upregulation of GABAA receptors. Changes in tNA
concentrations occur almost invariably when neuronal loss or
dysfunction is present (Moffett et al., 2013), which was the ratio-
nale to include this measure in the present study. Despite show-
ing decreased gray matter, the ACC did not exhibit a decreased
tNA/Cr concentration ratio. Thus, compromised neuronal integ-
rity with concomitant GABAA receptor upregulation appears to
be the less likely explanation, at least for the ACC. These findings
are in line with decreased prefrontal cortical thickness in a pre-
clinical model of long-term neuropathic pain (Seminowicz et al.,
2009) without concomitant changes in neuronal cell density
(Millecamps et al., 2010, data published in abstract form) and
with reports of the reversibility of gray matter decreases with
successful pain therapy (Rodriguez-Raecke et al., 2009). In con-
trast to the neuronal measures, the surrogate measure of tissue
water content partly explained gray matter decreases. T1 relax-
ation times exhibited positive linear relationships with GMVs,
indicating lower water content in areas with reduced graymatter.
Because of potential biases in T1mapping (Stikov et al., 2015), we
also analyzed proton-densitymaps (Mezer et al., 2013), which are
less dependent on lipids andmacromolecules than T1 times. This
analysis yielded very similar results, supporting the interpreta-
tion that GMV decreases in patients were related to decreased
water content. Dehydration and altered cerebral blood flow are
two potential explanations for the observed contribution ofwater
content. Althoughmanipulation of hydration state can influence
morphometric measures (Duning et al., 2005; Streitbu¨rger et al.,
Table 3. (continued)
Cuneus R
BPND 0.81 0.70
b 114.0b 0.001b 0.87 0.70b 114.0b 0.001b
T1/PD 0.12b 33.7b 0.001b 0.17b 65.6b 0.001b
Group 0.00 1.0 0.324 0.00 1.1 0.298
Group BPND 0.00 0.9 0.358 0.01 2.0 0.160
Group T1/PD 0.00 0.1 0.794 0.00 0.1 0.795
Postcentral gyrus R
BPND 0.40 0.22
b 13.6b 0.001b 0.47 0.22b 13.6b 0.001b
T1/PD 0.18b 14.6b 0.001b 0.24b 20.7b 0.001b
Group 0.05b 4.5b 0.039b 0.04 3.7 0.059
Group BPND 0.01 0.5 0.491 0.01 0.6 0.447
Group T1/PD 0.01 0.4 0.531 0.03 2.4 0.130
aGMV served as the dependent variable; flumazenil BPND , T1 time (water content) or proton density (PD), group (patients or controls), and the interaction terms served as the explanatory variables in themultiple regression analysis. L, Left;
R, right.
bSignificant with cluster-level correction across the whole brain at p 0.05.
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2012), it seems unlikely that differences in hydration status ex-
plain the finding of gray matter decreases in patients because
there is no evidence of compromised hydration in fibromyalgia,
at least to the best of our knowledge. An alternative explanation is
reduced cerebral blood flow (Franklin et al., 2013), which might
lead to decreased tissue water content by reduced extravasation.
Indeed, reduced blood flow has been described in the thalamus in
several chronic pain conditions, including fibromyalgia (for re-
view, see Williams and Gracely, 2006). Interestingly, the PCC,
which consistently shows decreased gray matter in chronic pain
(Smallwood et al., 2013), is part of the default mode network and
has a very high metabolic rate at rest (Cavanna and Trimble,
2006), making it perhaps particularly vulnerable to altered cere-
bral perfusion.
The regions showing graymatter decreases are consistent with
previous reports in fibromyalgia (Kuchinad et al., 2007; Luerding
et al., 2008; Lutz et al., 2008; Burgmer et al., 2009; Wood et al.,
2009; Puri et al., 2010; Robinson et al., 2011; Ceko et al., 2013;
Diaz-Piedra et al., 2016) and other chronic pain conditions
(Smallwood et al., 2013). In particular, bilateral insula and ACC
are key pain processing regions and the specific subregions found
here receive ascending nociceptive input (Dum et al., 2009). The
statistically most robust GMV decreases were observed in the
PCC and the precuneus, which negatively correlated with disease
duration and time since diagnosis: the longer patients had fibro-
myalgia, the smaller the GMVs. This replicates previous findings
in fibromyalgia patients (Kuchinad et al., 2007; Ceko et al., 2013).
It also speaks against the group difference being a false-positive
finding, which is important because the PCC was recently iden-
tified as a “hotspot” of false positives in human brain imaging
studies (Eklund et al., 2016). PCC, precuneus, and MPFC, also
exhibiting decreased GMV in the patients, are part of the default
mode network (Raichle et al., 2001), suggested to be disrupted in
chronic pain (Baliki et al., 2008). We further observed decreased
gray matter in the precentral gyrus, which is interesting because
sensorimotor regions have been found to be key for the classifi-
cation of chronic pain disorders based on morphometric mea-
sures (Labus et al., 2015).
In contrast to areas with decreased graymatter, the variance in
regions with increased GMVs was partly explained by GABAA
Figure 4. GMV increases in patients with fibromyalgia and their relationship with GABAA receptor concentration. Whole-brainmap of graymatter increases in patients compared with controls.
Results are presented at a voxelwise threshold of z 2.3 and a cluster-extent threshold of k 200, overlaid on themean anatomical image of thewhole sample (N 51). Scatter plots display GMV
(in mm3) against flumazenil BPND in each cluster. The axial image is displayed in neurological convention. Right, Right hemisphere.
Table 4. Relationship between graymatter density and flumazenil BPND
a
Region
Gray matter WLS regression
Volume (mm3) BPND GM density T p
Anterior inferior parietal sulcus 2406 3.08 0.45 2.98b 0.007b
Parietal lobule PF 3385 3.94 0.61 1.68 0.107
V3V 2865 3.42 0.52 1.60 0.123
Laterobasal amygdale 1301 2.42 0.67 2.05 0.052
Hippocampus cornu ammonis 2955 2.69 0.70 2.88b 0.008b
Hippocampus subiculum L 2505 2.67 0.72 1.63 0.116
Hippocampus subiculum R 2509 2.84 0.69 1.81 0.084
aRelationship between graymatter density and flumazenil BPND in regions showing a significant relationship in the Duncan et al. (2013) study. This table replicates theweighted least square (WLS) regression analysis done in Duncan et al.
(2013) to investigate the relationship between gray matter density and flumazenil BPND in our healthy control group (N 25), in regions from the Jülich histological atlas.
bSignificant with cluster-level correction across the whole brain at p 0.05.
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receptor concentration in addition to T1 relaxation times. In-
creased flumazenil binding could be due to increased neuronal
expression of GABAA receptors or increases in the amount of
neuronal matter. Increased expression of GABAA receptors has
been shown in the spinal cord of rats with neuropathic pain
(Lorenzo et al., 2013, data published in abstract form) and de-
creased supraspinal GABA concentration has been reported in
fibromyalgia (Foerster et al., 2012), perhaps leading to compen-
satory receptor increase. Interestingly, supraspinal GABAA re-
ceptor activation in rats decreases nociceptive thresholds and
produces hyperalgesia (Tatsuo et al., 1999), two typical findings
in fibromyalgia. Nevertheless, increased GABAA-receptor con-
centration is not sufficient to explain the finding of increased
GMVs. These might be related to inflammatory edema, which
could be reflected in the relationship of GMVs with T1 times, or
to increases in the amount of neuronal matter, reflected in the
relationship of GMV to GABAA receptor concentration. Candi-
date cellular mechanisms for increased neuronal matter are in-
creases in the number of neurons or in the size and/or number of
dendrites and synapses. An increased number of neurons seems
unlikely considering we investigated postmenopausal women. In
contrast, remodeling of synapses and dendrites is a well-known
phenomenon with increased usage or training (Lerch et al., 2011;
Zatorre et al., 2012) also in older age (Bloss et al., 2011). A pre-
clinical model of neuropathic pain showed more dendritic
branching and increased spine density in the MPFC (Metz et al.,
2009), indicating that neuronal matter is perhaps “induced” by
ongoing nociceptive input. GMV increases in the current study
concerned brain areas where visual and sensorimotor informa-
tion converge: the angular gyrus, the cuneus, and the postcentral
gyrus are involved in attention to the body and visuomotor co-
ordination (Prado et al., 2005; Macaluso and Maravita, 2010).
Thus, increased graymatter in these regionsmight reflect patients
allocating increased attentional resources to nociceptive and
other unpleasant sensory stimuli (Schweinhardt et al., 2007). The
finding that larger GMVs in the angular gyrus in patients were
associated with higher pain levels, the cardinal symptomof fibro-
myalgia, as well as higher anxiety and higher catastrophic think-
ing in relation to pain, supports this interpretation.
Limitations
Although state of the art, the measures used here are indirect
measures of the histological underpinnings of gray matter
changes. Therefore, their interpretation is not unambiguous. For
example, it is known that axon size can bias T1 measurements
(Harkins et al., 2016). Also, T1-weightedMR images are based on
T1 relaxation times; therefore, these twomeasures are not strictly
independent. Last, flumazenil binding has been used as a marker
of neuronal integrity (Heiss et al., 2001) but did not correlatewith
NAA, a measure of neuronal viability, which emphasizes that
flumazenil binding and NAA index different phenomena, with
flumazenil binding being representative of neuronal density or of
the availability of GABAA receptors and NAA of neuronal health.
Outlook and conclusions
Other chronic pain conditions show gray matter alterations in
similar brain regions as fibromyalgia (Smallwood et al., 2013),
and it will be interesting to establish whether the histological
underpinnings are similar to or different from the ones we de-
scribe here. Given the observation that gray matter decreases re-
solve with pain reduction in osteoarthritis (Rodriguez-Raecke et
al., 2009), low back pain (Seminowicz et al., 2013), and post-
traumatic headache (Obermann et al., 2009), it appears that neu-
rodegeneration does not play a role in these conditions. The
present study forms a basis for future work investigating specific
hypotheses regarding gray matter alterations in chronic pain, in-
cluding the relationship to cerebral perfusion or neuroinflamma-
tion. Also, animal models of chronic pain conditions will be
helpful to better characterize cerebral alterations induced by
long-term nociceptive input. Because chronic pain constitutes a
major health problem (Mansfield et al., 2016), understanding its
neurobiology is crucial. This study provides an important step
toward this goal by identifying several potential mechanisms un-
derlying gray matter alterations and indicating that cerebral neu-
rodegeneration is unlikely to play a major role in fibromyalgia.
This is in contrast to diseases with established neurodegeneration
and therefore indicates that different mechanisms can underlie
regional gray matter alterations, as measured with structural
MRI, in different clinical conditions.
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